Athersys, Inc. (NASDAQ:ATHX) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Athersys, Inc. (NASDAQ:ATHX) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Story continues below

On May2, 2018, the Board of Directors of Athersys, Inc. (the “Company”) amended Article III, Section4 of the Company’s bylaws to lower the vote required to remove a director, with or without cause, from the affirmative vote of the stockholders representing not less than two-thirds of the voting power of the issued and outstanding common stock of the Company to not less than a majority of the voting power of the issued and outstanding common stock of the Company. The description of the Company’s bylaws, as amended, is qualified in its entirety by the text of the bylaws, as amended, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 5.03. Financial Statements and Exhibits.

(d) Exhibits.

2


ATHERSYS, INC / NEW Exhibit
EX-3.1 2 d578554dex31.htm EX-3.1 EX-3.1 Exhibit 3.1 BYLAWS OF ATHERSYS,…
To view the full exhibit click here

About Athersys, Inc. (NASDAQ:ATHX)

Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI.

An ad to help with our costs